Qualcomm Life, Inc. Expands Collaboration with Novartis for Connected COPD Therapy; Plans to Launch the New Connected Breezhaler in 2019
Qualcomm Life Inc. and Novartis are expanding their global connected therapy management collaboration. Novartis will leverage Qualcomm Life's connectivity solutions to power its next-generation connected Breezhaler(TM), the inhaler for its Chronic Obstructive Pulmonary Disease (COPD) portfolio.
Novartis plans to launch the new connected Breezhaler in 2019 manufacturing, testing and regulatory approvals.